GENE ONLINE|News &
Opinion
Blog

2022-02-21| In-Depth

BIO CEO: Overcoming the Obstacles in Developing Gene Therapies

by Sahana Shankar
Share To
Right to Left, Top to Bottom: Barbara Lavery, Luca Issi, Lawrence Klein, Will Chou, and Gaurav Shah
In the last decade, there have been over 5000 clinical trials and yet only 2 approved drugs in the gene therapy space. This underlines the challenges in pre-clinical development, clinical trials, regulatory approvals and commercialization. Each vertical has witnessed tremendous improvements to encourage biopharma to invest heavily in gene therapies to address unmet clinical needs.   In a panel discussion at the BIO CEO & Investor Conference, industry experts reflected on their experiences of navigating the commercialization and approval landscape for cell and gene therapies. Moderated by Luca Issi, Senior Biotech Research Analyst at RNC Capital Market, the session included

It's free! Log in now to read

LATEST
Ascletis Announces U.S. IND Filing of Oral RdRp Inhibitor Drug Candidate ASC10 for COVID-19
2022-07-05
Breakthrough Zebrafish Genome Database Now Available
2022-07-05
WuXi Biologics Adds Microbial Fermentation to CDMO Offering in Hangzhou
2022-07-05
Sanofi Launches Nonprofit Brand To Distribute Medicines to Low-Income Countries
2022-07-05
As Private Equity Sale Becomes Less Likely, Novartis May Gravitate Towards Sandoz Spinoff
2022-07-04
Ascletis Begins Study of PD-L1 Antibody Candidate Against HIV
2022-07-04
Akebia Therapeutics Gains $55M Following Deal Termination by Otsuka Pharmaceutical
2022-07-04
EVENT
2022-07-27
BIO Asia–Taiwan 2022
Online and on-side
2022-08-03
BIOPLUS-INTERPHEX KOREA
Seoul
2022-09-09
ESMO 2022 Exhibition
Online and on-side
2022-09-21
CSCO Educational Book 2022
Xiamen
2022-09-21
RESI Boston
Boston
2022-09-26
Human Gene Therapy Conference
Australia
Scroll to Top